Search Results for:
-
Collaborations Between Biotech And Pharmaceutical Companies: Dec. 1, 2012 - April 18, 2013
GlycoVaxyn received an up-front payment and equity investment from GSK and is eligible for milestone payments and royalties on licensed vaccine candidates 12/20/12 Halozyme Therapeutics Inc. (San Diego) Pfizer Inc. (New York) $515 Worldwide collaboration and license agreement to develop and commercialize products that combine recombinant human hyaluronidase enzyme (rHuPH20) with biologics directed to up to six unnamed targets Halozyme will receive an initial payment of $8M, which includes the up -
Bench Press: BioWorld Looks at Translational Medicine
But researchers from the University of California at San Diego have developed a nanosponge for the opposite purpose, namely, to remove toxins from the bloodstream -
Rear-View Mirror Offers Preview of Road Forward
In 2009, when attendance at the convention in Atlanta fell to about 14,500 visitors from 20,000 in San Diego the year before and nearly 22,000 in Boston in 2007, many of the 170 sessions across 22 tracks focused on the minutiae of drug discovery and development, including biomarkers, clinical research and trials, drug delivery, exciting science, federal science and opportunities, global biotechnology issues, the biotech work force and translational medicine -
Clinic Roundup
Ceregene Inc., of San Diego, reported top-line data from its double-blind, randomized, controlled Phase IIb study of CERE-120 (AAV-neurturin), a gene therapy designed to deliver the neurotrophic factor neurturin, for Parkinson's disease -
Appointments and Advancements
Ambit Biosciences Inc., of San Diego, added David R. Parkinson to its board -
Other News To Note
La Jolla Pharmaceutical Co., of San Diego, said the FDA granted orphan designation to LJPC-6417 for fibrodysplasia ossificans progressiva (FOP -
Navigating Successful Biotechs: CEOs Need to be Visionaries
Enter Regulus Therapeutics Inc., of San Diego, (NASDAQ:RGLS), a company developing medicines targeting microRNA...He continues to play the sport in San Diego and also follows the fortunes of his favorite English soccer team, Manchester United -
ActoGeniX Series B to Move IBD Program to IND Stage
MediciNova Inc., of San Diego, said in an SEC filing that it entered an equity distribution agreement with Macquarie Capital Inc. (MCUS) to sell shares of common stock up to an aggregate of $6 million from time to time, through MCUS as sales agent -
Other News To Note
Mast Therapeutics Inc., of San Diego, said data presented at the Sickle Cell Disease Research & Educational Symposium in Miami showed that MST-188 reduced aggregation of both older and younger red blood cells, with a greater effect on older red blood cells...Santarus Inc., of San Diego, and Pharming Group, of Leiden, the Netherlands, said they submitted a biologics license application (BLA) for Ruconest (recombinant human C1 esterase inhibitor) for acute angioedema attacks in patients with -
Santaris Getting $10M Up Front in BMS Drug Discovery Pact
The company's freedom to operate in that area is contested, however, as Regulus Therapeutics Inc., of San Diego, claimed its patents provide it with broad coverage on the use of anti-miR-122 therapeutic agents, a claim Santaris is challenging -
Other News To Note
Pfenex Inc., of San Diego, and Agila Biotech Private Ltd., of Bangalore, India, a subsidiary of Strides Arcolab Ltd., entered a joint venture to develop, manufacture and commercialize an initial pipeline of six biosimilar products for the global market -
Auris Medical Gets $51M for Hearing Disorder Drugs
Otonomy Inc., of San Diego, raised $48.5 million in two funding rounds in 2010 -
Auris Medical Gets $51M for Hearing Disorder Drugs
Otonomy Inc., of San Diego, raised $48.5 million in two funding rounds in 2010 -
Santaris Getting $10M Up Front in BMS Drug Discovery Pact
The company's freedom to operate in that area is contested, however, as Regulus Therapeutics Inc., of San Diego, claimed its patents provide it with broad coverage on the use of anti-miR-122 therapeutic agents, a claim Santaris is challenging -
Avalon's Lichter: 'Laid-Back' Savvy Keeps Deal Flow Strong
said Jay Lichter, managing partner with Avalon Ventures in San Diego...He's a pretty laid-back guy," said Carmine Stengone, vice president of corporate development for Afraxis Inc., also of San Diego -
Appointments and Advancements
Trius Therapeutics Inc., of San Diego, added Seth H. Z. Fischer to its board -
Non-U.S. Clinical Trials & Regulatory Actions: March 2013
Company (Location) Product Description Indication Status Date AUTOIMMUNE Halozyme Therapeutics Inc. (San Diego) and Baxter International Inc. (London) HyQvia Combination of human normal immunoglobulin and recombinant human hyaluronidase designed as a replacement therapy Primary and secondary immunodeficiencies Received a positive opinion from the EMA's CHMP 3/25/13 Biogen Idec Inc. (Weston, Mass.) Tecfidera Dimethyl fumarate Relapsing-remitting multiple sclerosis Received a positive opinion -
Phase II Clinical Trials Update: March 2013
3/29/13 OncoSec Medical Inc. (San Diego) ImmunoPulse and NeoPulse DNA-based immunotherapy and NeoPulse therapy Solid tumors Phase II data demonstrated durable response results that were positive 3/26/13 Oxford BioMedica plc (Oxford, UK) TroVax Therapeutic vaccine Malignant pleural mesothelioma Started a Phase II trial 3/14/13 PsiOxus Therapeutics Ltd. (Oxford, UK) MT-102 A small molecule Cancer cachexia Completed patient enrollment in its Phase II trial 3/5/13 SymBio Pharmaceuticals Ltd. (Tokyo -
Phase III Clinical Trials Update: March 2013
talimogene laherparepvec, or T-VEC Melanoma Top-line Phase III data showed it met its primary endpoint of durable response rate when compared with subcutaneous granulocyte-macrophage colony-stimulating factor 3/21/13 Diffusion Pharmaceuticals LLC (Charlottesville, Va.) TSC Trans sodium crocetinate, an oxygen diffusion-enhancing compound Brain cancer Completed enrollment in a Phase II trial 3/18/13 Endocyte Inc. (San Diego) Etarfolatide Diagnostic imaging agent Ovarian cancer and non-small-cell -
American Academy of Neurology: March 2013
Company (Location) Product Description Indication Status Date Acadia Pharmaceuticals Inc. (San Diego) Pimavanserin The nondopaminergic blocker of serotonin 5-HT2A receptors Parkinson's disease psychosis Pivotal Phase III data demonstrated a highly significant antipsychotic efficacy on the nine-item SAPS-PD scale...an oral disease modifying therapy Multiple sclerosis Data showed that it significantly and consistently reduced the rate of brain volume loss 3/22/13 MediciNova Inc. (San Diego) MN-166
Category
Current Filters
- xSan Diego
Related Keywords
Categories
- x BioWorld Today (7951)
- x BioWorld Insight (610)
- x BioWorld International (416)
- x Bio Perspectives (103)
- x BioWorld Genomics Review (60)
- x State of the Industry Report (44)
- x BioWorld Snapshots (18)
- x Biotech Innovations (11)
- x RNAi Report (3)
- x Market-Leading Biotech Drugs (3)
- x Bioscan (1)
- x Executive Compensation Report (1)
- x Top 25 Drug Report (1)